Provided by Tiger Trade Technology Pte. Ltd.

Trevi Therapeutics, Inc.

11.10
-0.3600-3.14%
Post-market: 11.100.00000.00%17:27 EST
Volume:1.01M
Turnover:11.26M
Market Cap:1.42B
PE:-30.22
High:11.46
Open:11.41
Low:10.93
Close:11.46
52wk High:14.39
52wk Low:3.77
Shares:128.23M
Float Shares:97.09M
Volume Ratio:0.63
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3673
EPS(LYR):-0.4698
ROE:-36.87%
ROA:-23.93%
PB:7.50
PE(LYR):-23.62

Loading ...

Trevi Therapeutics Reports Positive Phase 2b Results for Nalbuphine ER in IPF Chronic Cough Trial

Reuters
·
Jan 23

Trevi Therapeutics Announces Publication of Data From the Phase 2B Ipf Chronic Cough Trial of Nalbuphine Er in the Journal of the American Medical Association (Jama)

THOMSON REUTERS
·
Jan 23

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)

TIPRANKS
·
Jan 22

Trevi Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CFO David C. Hastings

Reuters
·
Jan 13

BRIEF-Trevi Therapeutics Provides Strategic Updates Ahead Of Annual Lifesci Partners Corporate Access Event

Reuters
·
Jan 08

Trevi Therapeutics to Initiate Phase 2b Refractory Chronic Cough Trial in First Half of 2026

Reuters
·
Jan 08

Trevi Therapeutics Provides Strategic Updates Ahead of Annual Lifesci Partners Corporate Access Event Held During the J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 08

Trevi Therapeutics Inc - FDA End-of-Phase 2 Meeting Scheduled for Q1 2026

THOMSON REUTERS
·
Jan 08

Trevi Therapeutics Inc - Phase 2B Refractory Chronic Cough Trial to Start in H1 2026

THOMSON REUTERS
·
Jan 08

Trevi Therapeutics (TRVI): Evaluating Valuation After Appointing Veteran Biopharma CFO David Hastings

Simply Wall St.
·
Dec 20, 2025

Trevi Therapeutics Sets $522,000 Salary and Bonus Package for New CFO

Reuters
·
Dec 05, 2025

Trevi Therapeutics Names David Hastings CFO

MT Newswires Live
·
Dec 04, 2025

Trevi Therapeutics Names David Hastings as Chief Financial Officer

Reuters
·
Dec 04, 2025

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

THOMSON REUTERS
·
Dec 04, 2025

Trevi Therapeutics Inc - David Hastings to Assume CFO Role on January 6, 2026

THOMSON REUTERS
·
Dec 04, 2025

The Bull Case For Trevi Therapeutics (TRVI) Could Change Following Narrowed Losses and New Shelf Registration

Simply Wall St.
·
Nov 25, 2025

Trevi Therapeutics (TRVI): Evaluating Valuation Following Narrowed Loss and Financial Flexibility Moves

Simply Wall St.
·
Nov 23, 2025

Trevi Therapeutics Q3 Net Income USD -11.802 Million

Reuters
·
Nov 20, 2025

Stock Track | Trevi Therapeutics Soars 5.93% as Multiple Analysts Reaffirm Buy Ratings and Raise Price Targets

Stock Track
·
Nov 14, 2025

Trevi Therapeutics, Inc. : Oppenheimer Raises Target Price to $24 From $23

THOMSON REUTERS
·
Nov 14, 2025